Alimentary tract and metabolism
PHARMAC removed the Special Authority from macrogol 3350, a treatment for constipation.
This decision was following advice from the Gastrointestinal Subcommittee of the Pharmacology and Therapeutics Advisory Committee (PTAC) Subcommittee that macrogol 3350 was at least as clinically effective as lactulose and potentially better tolerated. An estimated 90,000 more people can now access this treatment.
Intravenous ferric carboxymaltose is now a potential option for treating patients with iron deficiency anaemia in the community.
We had previously listed this treatment in hospitals only. While we acknowledge that provision of infusion services in the community varied, we felt it was important to remove any barriers to community access that we were in control of – namely the absence of funding of the treatment in the community setting.
PHARMAC will continue to engage with the health sector around developing a community-based claiming and reimbursement model for pharmaceuticals delivered via primary care.
Last updated: 13 December 2018